Key Takeaways:
Soleno Therapeutics, Inc. (SLNO) faces a securities fraud class action lawsuit after its stock plunged over 26 percent on November 4, 2025, following disclosures of safety data concerns.
The lawsuit, filed on behalf of investors who purchased stock from March 26 to November 4, 2025, alleges the company made "materially false and/or misleading statements," according to a release from Kessler Topaz Meltzer & Check, LLP.
The core allegations claim Soleno misrepresented or concealed safety issues in its Phase 3 trial for diazoxide choline extended-release tablets (DCCR), its treatment for Prader-Willi syndrome. The filings specifically point to issues of excess fluid retention in clinical trial participants, which were allegedly downplayed. On November 4, 2025, Soleno acknowledged that a critical report from Scorpion Capital had disrupted the drug's launch, leading to lower patient starts and increased discontinuations.
The legal filings place the company's primary commercial product at risk, with a lead plaintiff deadline set for May 5, 2026. The stock's sharp decline reflects investor concern over DCCR's future commercial viability and the potential for adverse regulatory action.
The lawsuit, filed in the Northern District of California, seeks to recover damages for investors who lost money on their Soleno investments during the class period. Multiple law firms, including The Schall Law Firm and Kessler Topaz Meltzer & Check, LLP, have issued notices encouraging affected investors to come forward.
The allegations represent a significant challenge for the Redwood City, California-based pharmaceutical company, whose focus is on therapies for rare diseases. The negative attention on the DCCR trial's safety data could hamper patient adoption and prescriber confidence. Investors will be watching for the company's formal response to the lawsuit and any further updates on DCCR's market performance.
This article is for informational purposes only and does not constitute investment advice.
